0000000000224727

AUTHOR

E. Montesarchio

showing 3 related works from this author

Chloracne after release of TCDD at Seveso, Italy

1981

ABSTRACT The paper deals with clinical and epidemiological findings concerning persons showing skin lesions after release of TCDD at Seveso. A positive association was observed between geographical distribution of cases and levels of soil contamination. Gastro-intestinal tract impairments were more frequently observed in children with chloracne than in children from the same areas showing no skin lesions. To date, no major immunological involvement has been observed in samples of children exposed to TCDD.

ChloracneTCDDbusiness.industryPhysiologyMedicineTCDD; chlorinated dioxins; Seveso accidentSeveso accidentbusinessmedicine.diseaseSkin lesionchlorinated dioxins
researchProduct

Chloracne following Environmental Contamination by TCDD in Seveso, Italy

1981

Data are presented on the occurrence of chloracne, clinical symptoms and biochemical changes in 164 children following environmental contamination by TCDD from an industrial accident in Seveso, Italy. An overall positive association was found between the territorial distribution of chloracne cases and the different levels of soil contamination in the affected area. Individual risk factors such as condition and length of exposure, intake via contaminated foods, etc. were evaluated; no single factor appeared to be associated with chloracne. Disturbances of the gastrointestinal tract were more frequently observed in children affected with chloracne in those from the same areas having no skin l…

Malemedicine.medical_specialtyTCDDPolychlorinated DibenzodioxinsAdolescentEpidemiologyEnvironmental pollutionDioxinsChloracneTCDD; Seveso; ChloracneResidence CharacteristicsEnvironmental healthEpidemiologyAcne VulgarisMedicineAccidents OccupationalHumansChildbusiness.industrySingle factorGeneral MedicineSyndromeContaminationmedicine.diseaseDermatologyChloracneIndividual risk factorsItalyChild PreschoolEnvironmental PollutantsFemaleSevesoSkin lesionbusiness
researchProduct

Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial

2015

Background: Evidence suggests that metastatic colorectal carcinoma (mCRC) has a high level of intratumor heterogeneity. We carried out a quantitative assessment of tumor heterogeneity for KRAS, NRAS, BRAF and PIK3CA mutations, in order to assess potential clinical implications. Patients and methods: Tumor samples (n = 182) from the CAPRI-GOIM trial of first-line cetuximab + FOLFIRI in KRAS exon-2 wild-type mCRC patients were assessed by next-generation sequencing that allows quantitative assessment of mutant genes. Mutant allelic frequency was normalized for the neoplastic cell content and, assuming that somatic mutations usually affect one allele, the Heterogeneity Score (HS) was calculate…

OncologyNeuroblastoma RAS viral oncogene homologOrganoplatinum CompoundsColorectal cancerSettore MED/06 - Oncologia MedicaLeucovorinCetuximabCetuximab; Colorectal cancer; Mutations; Next-generation sequencing; Tumor heterogeneity; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Resistance Neoplasm; Fluorouracil; GTP Phosphohydrolases; Gene Frequency; High-Throughput Nucleotide Sequencing; Humans; Leucovorin; Membrane Proteins; Mutation; Organoplatinum Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Treatment Outcome; Hematology; OncologyColorectal Neoplasmmedicine.disease_causeGTP PhosphohydrolasesGTP PhosphohydrolasePhosphatidylinositol 3-KinasesGene FrequencyAntineoplastic Combined Chemotherapy ProtocolsMembrane ProteinClass I Phosphatidylinositol 3-KinasecolorectalCetuximabHigh-Throughput Nucleotide SequencingHematologyTreatment OutcomeOncologyFOLFIRIKRASFluorouracilColorectal Neoplasmsmedicine.drugHumanProto-Oncogene Proteins B-rafmedicine.medical_specialtyTumor heterogeneityClass I Phosphatidylinositol 3-KinasesProto-Oncogene Proteins p21(ras)Internal medicinemedicinecancerHumansneoplasmsAllele frequencyAntineoplastic Combined Chemotherapy ProtocolSettore MED/08 - ANATOMIA PATOLOGICAbusiness.industryCarcinomaOrganoplatinum CompoundMembrane ProteinsCancermedicine.diseaseColorectal cancerdigestive system diseasesDrug Resistance NeoplasmMutationCancer researchNext-generation sequencingNeoplastic cellCamptothecinPhosphatidylinositol 3-Kinasebusiness
researchProduct